Drug
Elacestrant clinical trials
Also written RAD1901, ORSERDU and ER-306323.
- studies test it
- 30
- open now
- 18
- in phase 3
- 4
- first study started
- 2009
Keep track of what changes. Save the elacestrant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 22
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 17
Stemline Therapeutics, Inc. (8) · SOLTI Breast Cancer Research Group (2) · Radius Pharmaceuticals, Inc. (2) · Kristina A. Fanucci (2) · Context Therapeutics Inc. (2) · University of Miami (1) · Jules Bordet Institute (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Anastrozole (3) · Abemaciclib (3) · Everolimus (2) · Exemestane (2) · Onapristone (2) · Fulvestrant (1) · mTOR Inhibitor (1) · Selective Estrogen Receptor Modulators (1)
Studies
Open first, then newest update. How each study uses elacestrant is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingPhase 2Stemline Therapeutics, Inc.NCT07766018Written as Elacestrant
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108Written as Elacestrant
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Written as Elacestrant
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953Written as Elacestrant
- Circulating Tumor DNARecruitingPhase 2Yale UniversityNCT06923527Written as Elacestrant
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingPhase 3Stemline Therapeutics, Inc.NCT06492616Written as Elacestrant
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498Written as elacestrant, palbociclib, abemaciclib, ribociclib
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingPhase 2Kristina A. FanucciNCT07222215Written as Elacestrant
- Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot yet recruitingPhase 2Jules Bordet InstituteNCT07753954Written as Elacestrant
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruitingPhase 3Women's Cancer Study Group GmbHNCT07242352Written as Elacestrant
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingPhase 1/2Kristina A. FanucciNCT07198724Written as Elacestrant
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07634601Written as Elacestrant
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingPhase 1/2NYU Langone HealthNCT07612215Written as Elacestrant
- Ph 2 Elacestrant in ER Positive Uterine SarcomasRecruitingPhase 2Dana-Farber Cancer InstituteNCT07467772Written as Elacestrant
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336Written as elacestrant and exemestane
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT05982093Written as Elacestrant
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06201234Written as Olaparib + Elacestrant
- Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNot yet recruitingPhase 2Azienda Ospedaliero-Universitaria CareggiNCT07005882Written as Elacestrant
- Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerTerminatedPhase 1/2Context Therapeutics Inc.NCT05618613Written as Elacestrant
- ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingPhase 2Stemline Therapeutics, Inc.NCT05596409Written as Elacestrant
See all 30 studies that test elacestrant →
Given in every arm · 9 — elacestrant is usual care beside what is tested
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingPhase 1BeOne MedicinesNCT06120283Written as Elacestrant
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingPhase 3MedSIRNCT06382948Written as Elacestrant
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerRecruitingPhase 1Stemline Therapeutics, Inc.NCT06638307Written as Elacestrant
- A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07209449Written as Elacestrant
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Written as Elacestrant
- A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07159451Written as Elacestrant
- Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast CancerActive, not recruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06691035Written as Elacestrant
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Written as Elacestrant
- A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast CancerCompletedPhase 1/2Carrick Therapeutics LimitedNCT05963997Written as Elacestrant Dihydrochloride
Codes
What other systems call elacestrant · ClinicalTrials.gg INT000889
- MeSH (NLM) C000626176elacestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FM6A2627A8ELACESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27278069elacestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120211ElacestrantOne source FDA
- DrugBank DB06374One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626176 | elacestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FM6A2627A8 | ELACESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27278069 | elacestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120211 | Elacestrant | One source FDA |
| DrugBank | DB06374 | — | One source Wikidata |
Also registered as elacestrant hydrochloride (UNII 8NZT0PR8AL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.